all glp 1 agonists Market Overview: GLP-1 and the Obesity Market | Blog glp-1_analogs [TUSOM | Pharmwiki]

These blockbuster medications have been associated with a range of health benefits, but a lack of data about how the drugs impact adults age 65 and up has clini

Furthermore,...

Combining the therapeutic approaches of GLP-1 agonists (which target extrahepatic mechanisms for metabolic disorders) with resmetirom (which target intrahepatic mechanisms for MASH and liver fibrosis) seems like a promising strategy for addressing fat accumulation, inflammation, and fibrosis associated with MASH.

The move could vastly expand access to the blockbuster medications.

A major new study reveals that women who discontinued these medications gained over 3 kg more during pregnancy compared to those who never used them